Amgen Inc.

Firmenich Sa

Northeastern University

Japan Tobacco Inc.

Jian Zhang

Julio Cesar Medina

Lawrence R McGee

Jonathan B Houze

Frank Kayser

Xiaoqi Chen

Barry L Karger

Liusheng Zhu

Jian Luo

Zhihua Ma

Rajiv Sharma

Jiwen Liu

Marc Labelle

Xianghong Wang

Jason A Duquette

Yingcai Wang

Sarah Lively

Zhihong Li

Michael J Schmitt

Jinqian Liu

Michael W Gribble, Jr

Kang Dai

Stephen J Shuttleworth

Daniel C H Lin

Rutger Van Sleeuwen

Jeffrey D Reagan

Michelle Akerman

Wei Qiu

Ying Sun

Kathleen S Keegan

Margaret F Weidner

Mark L Ragains

Justin N Huard

Masahiro Tanaka

Bei Shan

Takashi Inaba

Dustin L McMinn

Xiaolin Hao

Brian M Fox

Kexue Li

Pierre-Etienne Bouquerand

Simon Mark Jackson

Steven Marc Rubenstein

Valery Normand

Fei Zhang

Anandaraman Subramaniam

Noboru Furukawa

Atsuhito Yoshida

Shoichi Sagawa

Mingyue Zhou

Kazuyuki Sugimoto

Kiyosei Iio

Brian MacDougall

Amanda Schober

Dattatreya Banavara

Takuya Matsui

Denis Shcherbakov

Nobuya Ogawa

Masahiro Suzuki

Guosen Ye

Jeffrey W Donnelly

Sarah E Lively

Jinqain Liu

Described herein is a shelf stable powdered composition. More particularly, the composition includes a natural emulsifier, a carrier including inulin having a degree of polymerization equal or less than 15, and an active ingredient including a flavor or a perfume. Also described herein are a process for preparing such a composition and consumer products containing such a composition.

Shelf stable powdered composition

The aspects presented herein provide methods and compositions for the reduction or suppression of marine protein hydrolysate malodor by employing rice extract and/or a solid acid, preferably selected from malic acid, tartaric acid and citric acid.

Marine protein hydrosylate compositions with reduced malodor

Provided herein is a rice husk particles wherein at least 90%, by weight, of the total weight of the particles, has a diameter less than 25 &#x3bc;m.

Rice husk flow agent

Compounds of Formula I are useful inhibitors of CDK 4, CDK6, and FLT3. Such compounds are useful in treating cancer and various other disease conditions. Compounds of Formula I have the following structure:  and the definitions of the other variables are provided herein.

Fused tricyclic dual inhibitors of CDK 4/6 and FLT3

A polymer-based PLOT capillary column prepared by in situ copolymerization of a functional monomer and a crosslinking monomer, which enhances the strength of the polymer matrix, is disclosed. Also disclosed is a system comprising the polymer-based PLOT column coupled to a mass flow or concentration sensitive detector, for carrying out a chemical analysis method on samples separated by liquid chromatography using the column, and a process for using the system. Columns of the invention can be prepared in a robust fashion with a very narrow i.d., e.g., 5-15 &#x3bc;m. Thus, they are suitable for commercial use in ultratrace LC/MS proteomic analysis. Columns according to the invention are characterized by high resolving power and high column-to-column reproducibility. When these columns are coupled on-line with, e.g., ESI-MS detection, the resulting systems are capable of detecting the component parts of complex proteomic samples down to the low attomole to sub-attomole level.

Narrow bore porous layer open tube capillary column and uses thereof

A polymer-based PLOT capillary column prepared by in situ copolymerization of a functional monomer, which usually contains the retentive chemistries, and a crosslinking monomer, which enhances the strength of the polymer matrix, is disclosed. Also disclosed is a system comprising the polymer-based PLOT column coupled to a mass flow or concentration sensitive detector, for carrying out a chemical analysis method on samples separated by liquid chromatography using the column, and a process for using the system. Columns of the invention can be prepared in a robust fashion with a very narrow i.d., e.g., 5-15 &#x3bc;m. Thus, they are suitable for commercial use in ultratrace LC/MS proteomic analysis. Columns according to the invention are characterized by high resolving power and high column-to-column reproducibility. When these columns are coupled on-line with, e.g., ESI-MS detection, the resulting systems are capable of detecting the component parts of complex proteomic samples down to the low attomole to sub-attomole level.

The invention provides compounds, pharmaceutical compositions and methods for treating atherosclerosis, inflammation, thrombosis and other conditions and for decreasing or prevention of accumulation of cholesterol in a subject by modifying LCAT polypeptide.

Methods for treating atherosclerosis

The present invention provides compounds useful, for example, for modulating insulin levels in a subject and that have the general formulaQ-L-P-L-M-X-L-Awherein the definitions of the variables Q, L, P, L, M, X, Land A are provided herein. The present invention also provides compositions and methods for use of the compounds, for instance, for treatment of type II diabetes.

Compounds, pharmaceutical compositions and methods for use in treating metabolic disorders

The present invention provides compounds useful, for example, for modulating insulin levels in a subject and that have the general formulaQ&#x2014;L&#x2014;P&#x2014;L&#x2014;M&#x2014;X&#x2014;L&#x2014;Awherein the definitions of the variables Q, L, P, L, M, X, Land A are provided herein. The present invention also provides compositions and methods for use of the compounds, for instance, for treatment of type II diabetes.

Compounds, pharmaceutical compositions and methods that are useful in the treatment or prevention of metabolic and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the activity of proteins involved in lipid metabolism and cell proliferation.

Fused bicyclic nitrogen-containing heterocycles

Growing community of inventors

Foster City, CA, United States of America

Jian Zhang